Adderall Shortage: Pricing Crisis for ADHD Patients
Nationwide Shortage of ADHD Medications Leads to Price Surge
A nationwide shortage of drugs that treat attention deficit hyperactivity disorder (ADHD) has forced some patients to shell out hundreds more for pricey, brand-name alternatives. A new analysis from USA Today found that the prices that retail community pharmacies pay for common ADHD medications have outpaced inflation, and in some cases, have doubled or tripled in the last year.
The Shortage
The Food and Drug Administration announced a shortage of Adderall in October 2022 due to “ongoing intermittent manufacturing delays” at companies that make the drug. According to recent studies, an estimated 6 million children and 11 million adults suffer from ADHD. Adderall is a popular stimulant prescribed to improve focus and attention.
The Impact
The Adderall shortage spurred patients to seek out alternatives — in turn, those ADHD meds became hard to find and prices increased. A Delaware mom, who wishes to remain anonymous, shared her struggles with USA Today. Her 17-year-old daughter and husband also have ADHD, and their doctor switched her daughter’s prescription to Vyvanse, the only option available.
The Cost
The mom said that the monthly amount they pay after insurance rose from less than $20 to $300. Without insurance, a supply of 100 capsules of Vyvanse costs around $1,306, according to Drugs.com. GoodRx reports that generic Vyvanse costs $100, while the brand-name Vyvanse starts at $369, which is slightly higher than the cost of brand-name Adderall.
The LEading to Financial Burden
The price surge has led to a financial burden for many families. The mom explained, "With medication and accommodations at school, my daughter is a straight-A student. Without the medication, she’s failing. It’s that stark of a difference."
DEA’s Response
The Drug Enforcement Administration said it has been adjusting its quota restrictions to increase production of ADHD stimulants. In a letter early last month, the agency wrote, "DEA has been in communication with the relevant manufacturers, and 17 out of 18 manufacturers have informed us that they will use their allotted quota amounts and increase production of stimulant medications."
Conclusion
The ADHD drug shortage has left many patients in a difficult position, forced to pay exorbitant prices for medication or seek out alternatives. The financial burden this creates can be substantial, and the impact on quality of life should not be underestimated.
FAQs
Q: What is the cause of the Adderall shortage?
A: The Food and Drug Administration announced a shortage of Adderall in October 2022 due to “ongoing intermittent manufacturing delays” at companies that make the drug.
Q: How many people are affected by ADHD?
A: According to recent studies, an estimated 6 million children and 11 million adults suffer from ADHD.
Q: What are the prices of alternative ADHD medications?
A: The prices of alternative ADHD medications, such as Vyvanse, have increased significantly. Without insurance, a supply of 100 capsules of Vyvanse costs around $1,306, according to Drugs.com.
Q: How is the DEA responding to the shortage?
A: The Drug Enforcement Administration has been adjusting its quota restrictions to increase production of ADHD stimulants.
